澳大利亚抑郁症遗传研究中昼夜节律亚型的临床与遗传相关性
该横断面研究基于澳大利亚抑郁症遗传研究,以至少三项昼夜节律相关特征界定「昼夜节律亚型」抑郁,共2604人(23%)符合。该亚型起病更早、临床特征更重,对SSRI和SNRI反应更差、副作用更多,并与多种精神疾病及代谢炎症相关多基因风险评分升高相关。
要点
- 以社交时差、季节性、睡眠中点延迟、晚睡型、晨疲乏、嗜睡中至少三项界定昼夜节律亚型。
- 昼夜节律亚型起病更早,伴更多(轻)躁狂样、精神病样体验、自杀风险及躯体不适。
- 该亚型对SSRI(OR 0.88)和SNRI(OR 0.89)反应更差,副作用更多。
核心结论
- 研究结果支持昼夜节律亚型抑郁具有表面效度和潜在临床实用性,尚待独立重复验证。
研究设计与样本
- 横断面数据来自全国性澳大利亚抑郁症遗传研究,按至少三项二分昼夜节律特征分类为昼夜节律或非昼夜节律亚型。
主要发现
- 2604名参与者(23%;80%女性;平均年龄37.87±13.62岁)符合昼夜节律亚型。
- 昼夜节律亚型起病年龄更早(P<0.001),(轻)躁狂样和精神病样体验、自杀风险、心理困扰及躯体不适更严重(均P<0.001)。
- 昼夜节律亚型抑郁发作期体重增加更常见(P<0.001),SSRI反应更差(OR 0.88 [95%CI 0.82,0.94]),SNRI反应更差(OR 0.89 [95%CI 0.83,0.97]),副作用更多。
- 昼夜节律亚型与注意缺陷多动障碍(OR 1.11 [95%CI 1.06,1.17])、重性抑郁(OR 1.11 [95%CI 1.06,1.16])、焦虑(OR 1.10 [95%CI 1.04,1.15])、双相障碍(OR 1.09 [95%CI 1.04,1.14])多基因风险评分升高相关。
- 昼夜节律亚型与BMI(OR 1.09 [95%CI 1.05,1.14])、甘油三酯(OR 1.10 [95%CI 1.06,1.16])、白细胞介素-6(OR 1.08 [95%CI 1.03,1.13])、胰岛素抵抗(OR 1.08 [95%CI 1.04,1.13])、睡眠中点延迟(OR 1.15 [95%CI 1.10,1.21])、失眠(OR 1.08 [95%CI 1.03,1.13])及晚睡型(OR 0.68 [95%CI 0.65,0.71])多基因风险评分相关。
关键数值与推荐
- 昼夜节律亚型界定标准:社交时差、季节性、睡眠中点延迟、晚睡型、晨疲乏、嗜睡六项中至少满足三项。
- SSRI反应OR 0.88(95%CI 0.82,0.94),SNRI反应OR 0.89(95%CI 0.83,0.97)。
- 注意缺陷多动障碍多基因风险评分OR 1.11(95%CI 1.06,1.17),重性抑郁OR 1.11(95%CI 1.06,1.16)。
- 焦虑多基因风险评分OR 1.10(95%CI 1.04,1.15),双相障碍OR 1.09(95%CI 1.04,1.14)。
- BMI多基因风险评分OR 1.09(95%CI 1.05,1.14),甘油三酯OR 1.10(95%CI 1.06,1.16)。
临床怎么用
- 对抑郁患者可筛查社交时差、季节性、睡眠中点延迟、晚睡型、晨疲乏和嗜睡,识别昼夜节律亚型。
- 识别该亚型有助于预判起病更早、症状更重及对SSRI/SNRI反应更差和副作用更多。
- 该亚型与代谢炎症及多种精神疾病遗传风险相关,提示需关注共病与个体化治疗。
局限性
- 研究为横断面设计,药物反应基于自我报告,不能推断因果关系。
- 结论尚待独立样本重复验证,其生物学机制和预测效用需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although commonly accepted depressive subtypes reflect phenotypic differences, there has been minimal progress in identification of discrete pathophysiological pathways, biomarkers or differential therapeutic approaches to effectively guide clinical management. AIMS: To test the biological validity and clinical utility of a circadian subtype of depression on the basis of clinical course, differential medication response (self-reported) and genetic risk profile. METHOD: Cross-sectional data were drawn from the nationwide Australian Genetics of Depression Study. Participants were classified as having a 'circadian' or 'non-circadian' subtype of depression on the basis of meeting criteria for at least three binary circadian-associated features: social jetlag, seasonality, delayed sleep midpoint, evening chronotype, morning tiredness and hypersomnia. Clinical course characteristics were compared. Associations with response to commonly prescribed antidepressants and polygenic risk scores for mental disorders and sleep, circadian, metabolic and inflammatory traits were investigated using logistic regression models. RESULTS: A total of 2604 participants (23%; 80% female; mean age 37.87 ± 13.62 years) had a circadian subtype. They reported an earlier age at onset (P < 0.001), more severe clinical features including (hypo)manic-like and psychotic-like experiences, suicidality, psychological distress and somatic complaints (all P < 0.001), weight gain during depressive episodes (P < 0.001), poorer response to selective serotonin reuptake inhibitors (odds ratio 0.88 [95% CI 0.82, 0.94]) and serotonin-noradrenaline reuptake inhibitors (odds ratio 0.89 [95% CI 0.83, 0.97]), and more side-effects compared with those with a non-circadian subtype. Having a circadian subtype was associated with higher polygenic risk scores for attention-deficit hyperactivity disorder (odds ratio 1.11 [95% CI 1.06, 1.17]), major depression (odds ratio 1.11 [95% CI 1.06, 1.16]), anxiety (odds ratio 1.10 [95% CI 1.04, 1.15]), bipolar disorder (odds ratio 1.09 [95% CI 1.04, 1.14]), body mass index (odds ratio 1.09 [95% CI 1.05, 1.14]), triglycerides (odds ratio 1.10 [95% CI 1.06, 1.16]), interleukin-6 (odds ratio 1.08 [95% CI 1.03, 1.13]), higher insulin resistance (odds ratio 1.08 [95% CI 1.04, 1.13]), later sleep midpoint (odds ratio 1.15 [95% CI 1.10, 1.21]), insomnia (odds ratio 1.08 [95% CI 1.03, 1.13]) and later chronotype (odds ratio 0.68 [95% CI 0.65, 0.71]). CONCLUSIONS: These findings support the face validity and potential clinical utility of a circadian subtype of depression as a clinical profile. Pending independent replication, investigation of its biology and predictive utility are warranted.
引用
- Tonini E, Crouse JJ, Shin M, et al. Clinical and genetic correlates of a circadian subtype of depression in the Australian Genetics of Depression Study. Br J Psychiatry. 2026. PMID: 42901213. doi:10.1192/bjp.2026.10798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。